Trial Profile
A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors YM BioSciences
- 30 May 2011 Status changed from recruiting to discontinued.
- 10 Feb 2011 Recruitment targets are lagging and the trial is under review as the compnay focuses support on more advanced trials, according to a YM BioSciences media release
- 24 Jan 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12610000560099).